Green Thumb Industries (GTI) account plan
Cannabis products manufacturer and retailer
At a glance
Green Thumb Industries is a Chicago cannabis brand maker and RISE Dispensaries retailer in fourteen U.S. markets with approximately 5,000 employees.
Green Thumb Industries (GTI) is a Chicago-headquartered, vertically integrated cannabis company founded in 2014: it grows and processes cannabis, makes consumer packaged goods in twenty manufacturing facilities and sells them wholesale to licensed dispensaries and through its own RISE Dispensaries. It operates in fourteen U.S. markets, from Illinois, Florida and Pennsylvania to New York, Ohio, Minnesota and Virginia, and employs approximately 5,000 people. FY2025 revenue was $1,175,295 thousand, up 3%, with Adjusted EBITDA of $341,589 thousand and net income attributable to GTI of $114,152 thousand. Its shares trade on the CSE (GTII) and OTCQX (GTBIF), and Super Voting Shares held by Benjamin Kovler, Andrew Grossman and Anthony Georgiadis concentrate voting control.
Business units
Retail (RISE Dispensaries)
69% of Q3 2026 revenue (71% of FY2025 revenue)The national RISE Dispensaries chain sells GTI-made and third-party cannabis products in all fourteen states, with 130 open and operating stores at September 30, 2026 (108 a year earlier). Q3 2026 segment revenue rose 10% to $224,575 thousand, led by Minnesota, new and acquired stores, Florida, Maryland and Virginia; same-store sales on 108 stores grew 3%.
Consumer Packaged Goods
31% of Q3 2026 revenue (29% of FY2025 revenue)Manufactures and distributes the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles and RYTHM brands, now licensed from RYM, across flower, pre-rolls, concentrates, vape, edibles and other categories. Q3 2026 segment revenue rose 16% to $189,344 thousand before eliminations; RYTHM ranks number one nationally in branded flower and Dogwalkers number one in uninfused pre-rolls.
Strategic priorities
- Retail expansion in Florida and beyond
- Twenty-two stores were opened or acquired in the year to September 30, 2026; GTI has 27 Florida dispensaries and plans three to five more in Florida before year end, "10 plus" in Florida next year and one or two in Ohio.
- New adult-use and medical markets
- Virginia adult-use sales begin July 1, 2027, where GTI is one of five licensed operators with six RISE dispensaries and two cultivation facilities; in Texas it holds a conditional license since April 1 and bought a wholesale facility near Fort Worth.
- Federal rescheduling and tax relief
- Medical cannabis moved to Schedule III effective April 28, 2026, so Section 280E no longer applies to the medical business; GTI is pursuing DEA registration in Florida and Virginia and awaits the broader rescheduling decision.
- Brand leadership in CPG
- GTI holds the number one market position in Illinois, Maryland and New Jersey, and its strategic thesis is "that distributing brands at scale will win".
- Disciplined capital allocation
- Capital goes to growth capex, M&A and buybacks; since Q4 2023 more than $200 million has been returned through about 29.5 million shares repurchased, and a new $50,000 thousand program started September 23, 2026.
Latest results
In Q3 2026 (quarter ended September 30, 2026), revenue rose 11% to $324,412 thousand, driven by Minnesota adult-use, new and acquired stores and growth in Florida, New Jersey, New York, Ohio and Virginia, partly offset by price compression. Gross margin fell to 45% from 49%, mainly because of $15,750 thousand of RYM brand licensing fees, and income from operations dropped 32% to $25,089 thousand. GTI posted a net loss attributable of $4,827 thousand, versus net income a year earlier that included the IP sale gain; Normalized EBITDA rose to $89,402 thousand from $80,163 thousand. Nine-month revenue was $931,285 thousand, up 8%. Management expects Q4 revenue "flat to down slightly due to the pricing environment" and continued margin compression.
Investments and deals
- RYTHM, Inc. (RYM) stake and consolidation
- GTI owns approximately 33% of RYM, extended it convertible notes of $27,000 thousand (May 2025) and $45,000 thousand (August 2025), and began consolidating it on October 10, 2026 after the 49.99% ownership cap was removed.
- Brand IP sale and license-back
- In 2025 GTI sold its brand intellectual property to RYM and licenses it back; from April 1, 2026 the revenue-based fee was replaced by fixed annual licensing fees.
- Retail acquisitions
- Seven retail stores were bought in 2025 for about $19,308 thousand; in the nine months to September 30, 2026 GTI took control of retail operations through management services agreements for total consideration of $62,551 thousand.
- Capex
- 2026 capex is guided at approximately 80 million excluding real estate, with $20 million spent in Q3 2026.
- Share buybacks
- 13,438,787 shares were repurchased in the nine months to September 30, 2026 at a $5.78 average, after 7,209,875 shares in 2025.
Challenges and risks
- Price compression
- Price compression and competition weighed on both segments, notably in Massachusetts, New Jersey and Pennsylvania; management expects "some continued compression" in coming quarters.
- Brand licensing fees squeeze margins
- RYM licensing fees of $40,478 thousand in the first nine months of 2026 pushed gross margin to 46% from 50%.
- Federal illegality and banking
- Broader rescheduling is still pending, Section 280E still applies outside the medical business, banking access is restricted and U.S. multistate operators cannot list on U.S. exchanges.
- Competition from hemp-derived THC
- Intoxicating hemp products compete with licensed cannabis until a federal law effectively prohibits them; Kovler says "That product has to go away."
- Rising operating costs
- SG&A reached 38% of revenue in Q3 2026, with normalized operating costs about $88 million vs $75 million, mainly from 22 incremental retail stores.
What leadership says
“Navigating that uncertainty isn't a side skill for us. It's a core competency.”
“What institutions need is federal certainty, clarity on scheduling and clarity on taxes.”
“Medical cannabis is now on Schedule III of the controlled substances act, the first domino has fallen.”
“We build brands people love, invest in our team, and protect the balance sheet.”
Where a supplier can help
- Store build-out and fit-out
- The retail expansion priority ("10 plus" Florida stores next year, Ohio openings) creates demand for store construction, fixtures, security and point-of-sale systems.
- Cultivation and processing capacity
- Virginia adult-use from July 1, 2027 and the Texas wholesale hub need added cultivation, extraction and packaging capacity, within about 80 million of 2026 capex.
- Retail cost efficiency
- Rising operating costs from 22 incremental stores and continued price compression make workforce scheduling, inventory and pricing tools relevant to protecting margins.
- Compliance and DEA registration
- The rescheduling priority and DEA registration of medical operations in Florida and Virginia call for regulatory compliance, tracking and tax advisory support.
- Finance integration of RYTHM
- Consolidating RYM from October 10, 2026 as a business combination achieved in stages requires accounting, valuation and systems integration work.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Green Thumb Industries (GTI)?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended December 31, 2025
- Green Thumb Industries (GTI) is a Chicago-headquartered national cannabis consumer packaged goods company and retailer, founded in 2014, operating in fourteen U.S. markets with approximately 5,000 employees; its shares trade on the CSE (GTII) and OTCQX (GTBIF).
- FY2025 revenue was $1,175,295 thousand, up 3%; gross margin fell to 49% from 53% on price compression and a new brand licensing fee; income from operations dropped 39% to $137,700 thousand.
- Net income attributable to GTI rose 56% to $114,152 thousand, driven by $125,946 thousand of fair value gains on RYM warrants; Adjusted EBITDA was $341,589 thousand (2024: $371,318 thousand), Normalized EBITDA $348,390 thousand.
- Two segments: Retail (RISE Dispensaries, 113 stores at year end) was 71% of revenue and Consumer Packaged Goods (&Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, RYTHM) 29%.
- In 2025 GTI sold its brand intellectual property to RYTHM, Inc. (RYM, formerly Agrify) and licenses it back; GTI owns approximately 33% of RYM and extended it convertible notes of $27,000 thousand (May 2025) and $45,000 thousand (August 2025).
- Strong cash generation: operating cash flow $294,926 thousand, cash $274,298 thousand at year end; 7,209,875 shares repurchased in 2025 at an average $4.84, and $117,814 thousand returned through buybacks since the program began.
- Growth comes from new adult-use markets (Minnesota from September 2025, Ohio from August 2024), store openings and acquisitions (seven retail stores bought in 2025 for about $19,308 thousand).
- Key risks: federal illegality and Section 280E taxation, price compression and competition (including hemp-derived THC products, which a 2025 federal law will effectively prohibit from November 12, 2026), restricted banking, and voting control concentrated in Super Voting Shares held by Benjamin Kovler, Andrew Grossman and Anthony Georgiadis.
- A December 18, 2025 Executive Order directed the rescheduling of cannabis to Schedule III, which would remove Section 280E; the company says implications are "not yet fully understood".
- Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue was $324,412 thousand, up 11% year over year; nine-month revenue $931,285 thousand, up 8%, driven by Minnesota adult-use (from September 17, 2025), new and acquired stores and growth in Florida, New Jersey, New York, Ohio and Virginia.
- Gross margin fell to 45% from 49%, mainly because of RYM brand licensing fees of $15,750 thousand in the quarter (license moved to fixed annual fees from April 1, 2026).
- Income from operations dropped 32% to $25,089 thousand; net loss attributable to GTI of $4,827 thousand ($(0.02) per share) versus net income of $23,288 thousand a year earlier, which included the IP sale gain.
- Adjusted EBITDA $73,652 thousand; Normalized EBITDA (excluding license fees) $89,402 thousand versus $80,163 thousand.
- 130 open and operating Retail stores at September 30, 2026 (108 a year earlier); twenty-two opened or acquired since September 30, 2025. Retail was 69% and CPG 31% of revenue.
- Tax expense fell to $28,062 thousand from $49,122 thousand after the DOJ final order moving state-legal medical cannabis to Schedule III, effective April 28, 2026.
- GTI began consolidating RYTHM, Inc. on October 10, 2026, after RYM shareholders removed the 49.99% ownership cap on GTI's warrants and notes; the financial effect could not yet be estimated.
- Cash $316,000 thousand; 13,438,787 shares repurchased in nine months at $5.78 average; new $50,000 thousand buyback program from September 23, 2026.
- Green Thumb Industries Q3 2026 earnings call transcript
- Q3 2026 revenue was $324 million, up 11%; normalized EBITDA $89 million (about 28% of revenue); operating cash flow $58 million; cash $316 million.
- Ben Kovler says a U.S. listing alone does not change valuation: "What institutions need is federal certainty, clarity on scheduling and clarity on taxes."
- Section 280E no longer applies to the medical business; certain medical licenses are DEA-registered in Florida and Virginia.
- Same-store sales across 108 stores grew 3%, the first positive comp since Q3 2024; RYTHM is number one in branded flower and Dogwalkers number one in uninfused pre-rolls nationally.
- Expansion: six new RISE stores in the quarter and three more in Florida after it (27 in Florida, more than 130 nationally); 10 plus Florida stores planned for next year; 2026 capex about 80 million excluding real estate.
- Virginia (adult-use from July 1, 2027, one of five licensed operators) and Texas (conditional license, wholesale facility near Fort Worth bought) are the main state catalysts.
- Kovler is "not interested in bifurcating the business" to uplist the medical part; GTI trades at "roughly 4 to 5" times EBITDA.
- Q4 revenue expected flat to down slightly; continued price compression expected; RYTHM consolidated from October 10.
- Green Thumb Industries Q2 2026 earnings call transcript
- Q2 2026 revenue was $307 million, up 5%; normalized EBITDA $84 million (about 28%); cash from operations $29 million; cash $284 million, over $1 a share.
- Ben Kovler: medical cannabis on Schedule III means "the first domino has fallen"; GTI is preparing to uplist "the business in full, not in part" and is in dialogue with both major exchanges.
- Virginia (adult-use from July 1, 2027) and Texas (conditional license since April 1) represent access for roughly 12% of the U.S. population.
- Kovler sees THC beverages as distinct from intoxicating hemp: a "5 or 10 milligram ready-to-drink beverage is different from a 1,000 milligram gummy".
- Gross margin 45% vs 50% due to $17.5 million brand licensing fees; normalized operating costs $84 million vs $74 million after compensation investments.
- Same-store sales on 103 stores down about 1%; price compression in Massachusetts, New Jersey and Pennsylvania; Q3 revenue guided flat.
- About 8 million shares repurchased in the quarter at just over $6; capex guidance about $80 million for 2026; GTI named on TIME's list of America's Best Companies.
- RYTHM consolidation from as early as October 10, 2026 depends on an August 10 RYM shareholder vote; "Nothing will change economically".
Questions about Green Thumb Industries (GTI)
What does Green Thumb Industries do?
Green Thumb grows and processes cannabis, manufactures branded products such as RYTHM, Dogwalkers and incredibles, and sells them wholesale and through its RISE Dispensaries in fourteen U.S. markets.
What is Green Thumb Industries' revenue?
FY2025 revenue was $1,175,295 thousand, up 3%. Q3 2026 revenue was $324,412 thousand, up 11%.
How many employees does Green Thumb have?
Green Thumb employs approximately 5,000 people, including approximately 2,500 in retail and approximately 2,000 in cultivation and processing.
Who leads Green Thumb Industries?
Benjamin Kovler is Founder, Chairman and CEO, Anthony Georgiadis is President and Mathew Faulkner is CFO.
How many stores does Green Thumb operate?
GTI had 130 open and operating Retail stores at September 30, 2026, up from 108 a year earlier, mostly under the RISE Dispensaries name.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)